I'll survey the CLDN18.2 competitive landscape in gastric/GEJ cancer. Let me start by exploring the database.
{
"indications": {
"ES-SCLC": {
"targets": [
"DLL3",
"PD-L1",
"SEZ6"
],
"n_trials": 7
},
"Gastric/GEJ": {
"targets": [
"CLDN18.2",
"PD-1"
],
"n_trials": 7
},
"HER2+ Breast": {
"targets": [
"HER2"
],
"n_trials": 5
},
"HER2-low Breast": {
"targets": [
"HER2"
],
"n_trials": 1
}
}
}{
"count": 6,
"trials": [
{
"nct": "NCT03504397",
"sponsor": "Astellas",
"drug": "Zolbetuximab",
"indication": "Gastric/GEJ",
"target": "CLDN18.2",
"modality": "Naked monoclonal antibody",
"phase": "PHASE3",
"status": "COMPLETED",
"n_enroll": 565,
"start_year": 2018,
"line": "1L",
"primary_endpoint": "Progression-free survival",
"control_arm": "Chemotherapy"
},
{
"nct": "NCT03653507",
"sponsor": "Astellas",
"drug": "Zolbetuximab",
"indication": "Gastric/GEJ",
"target": "CLDN18.2",
"modality": "Naked monoclonal antibody",
"phase": "PHASE3",
"status": "COMPLETED",
"n_enroll": 507,
"start_year": 2018,
"line": "1L",
"primary_endpoint": "Overall survival",
"control_arm": "Chemotherapy"
},
{
"nct": "NCT04581473",
"sponsor": "CARsgen",
"drug": "CT041 (satricabtagene autoleucel)",
"indication": "Gastric/GEJ",
"target": "CLDN18.2",
"modality": "CAR-T (autologous)",
"phase": "PHASE2",
"status": "RECRUITING",
"n_enroll": 100,
"start_year": 2020,
"line": "3L+",
"primary_endpoint": "Objective response rate",
"control_arm": "Single arm"
},
{
"nct": "NCT05262491",
"sponsor": "LaNova Medicines",
"drug": "LM-302 (CLDN18.2 ADC)",
"indication": "Gastric/GEJ",
"target": "CLDN18.2",
"modality": "Antibody-drug conjugate",
"phase": "PHASE1",
"status": "RECRUITING",
"n_enroll": 60,
"start_year": 2022,
"line": "2L+",
"primary_endpoint": "Safety / objective response rate",
"control_arm": "Single arm"
},
{
"nct": "NCT05867251",
"sponsor": "Innovent",
"drug": "IBI389 (CLDN18.2 x CD3)",
"indication": "Gastric/GEJ",
"target": "CLDN18.2",
"modality": "T-cell engager (bispecific)",
"phase": "PHASE1",
"status": "RECRUITING",
"n_enroll": 80,
"start_year": 2023,
"line": "2L+",
"primary_endpoint": "Safety / dose escalation",
"control_arm": "Single arm"
},
{
"nct": "NCT04379596",
"sponsor": "Zai Lab",
"drug": "Zolbetuximab",
"indication": "Gastric/GEJ",
"target": "CLDN18.2",
"modality": "Naked monoclonal antibody",
"phase": "PHASE3",
"status": "ACTIVE_NOT_RECRUITING",
"n_enroll": 200,
"start_year": 2020,
"line": "1L",
"primary_endpoint": "Progression-free survival",
"control_arm": "Chemotherapy"
}
]
}Let me get fuller detail on the key differentiated assets and check the broader Gastric/GEJ context (PD-1 trials too).
{
"nct": "NCT04581473",
"sponsor": "CARsgen",
"drug": "CT041 (satricabtagene autoleucel)",
"indication": "Gastric/GEJ",
"target": "CLDN18.2",
"modality": "CAR-T (autologous)",
"phase": "PHASE2",
"status": "RECRUITING",
"n_enroll": 100,
"start_year": 2020,
"line": "3L+",
"primary_endpoint": "Objective response rate",
"control_arm": "Single arm"
}{
"nct": "NCT05262491",
"sponsor": "LaNova Medicines",
"drug": "LM-302 (CLDN18.2 ADC)",
"indication": "Gastric/GEJ",
"target": "CLDN18.2",
"modality": "Antibody-drug conjugate",
"phase": "PHASE1",
"status": "RECRUITING",
"n_enroll": 60,
"start_year": 2022,
"line": "2L+",
"primary_endpoint": "Safety / objective response rate",
"control_arm": "Single arm"
}{
"nct": "NCT05867251",
"sponsor": "Innovent",
"drug": "IBI389 (CLDN18.2 x CD3)",
"indication": "Gastric/GEJ",
"target": "CLDN18.2",
"modality": "T-cell engager (bispecific)",
"phase": "PHASE1",
"status": "RECRUITING",
"n_enroll": 80,
"start_year": 2023,
"line": "2L+",
"primary_endpoint": "Safety / dose escalation",
"control_arm": "Single arm"
}{
"count": 1,
"trials": [
{
"nct": "NCT02954536",
"sponsor": "BMS",
"drug": "Nivolumab + chemo",
"indication": "Gastric/GEJ",
"target": "PD-1",
"modality": "Checkpoint inhibitor (mAb)",
"phase": "PHASE3",
"status": "COMPLETED",
"n_enroll": 1581,
"start_year": 2017,
"line": "1L",
"primary_endpoint": "Overall survival",
"control_arm": "Chemotherapy"
}
]
}| Drug | Sponsor | Modality | Phase | Line | Status | N | Design |
|---|---|---|---|---|---|---|---|
| Zolbetuximab | Astellas (SPOTLIGHT) | Naked mAb | 3 | 1L | Completed | 565 | vs chemo, PFS |
| Zolbetuximab | Astellas (GLOW) | Naked mAb | 3 | 1L | Completed | 507 | vs chemo, OS |
| Zolbetuximab | Zai Lab (China bridge) | Naked mAb | 3 | 1L | Active | 200 | vs chemo, PFS |
| CT041 (satri-cel) | CARsgen | Autologous CAR‑T | 2 | 3L+ | Recruiting | 100 | Single arm, ORR |
| LM‑302 | LaNova | ADC | 1 | 2L+ | Recruiting | 60 | Single arm |
| IBI389 | Innovent | CD3 bispecific (TCE) | 1 | 1 | 2L+ | Recruiting | 80 |
(Context: the only PD‑1 asset in this dataset for the indication is BMS nivolumab+chemo, 1L, the established checkpoint backbone.)
1L is owned by the naked-antibody class. Zolbetuximab is the validated first mover and effectively the standard-setter — two completed Phase 3s (PFS + OS readouts) plus a Zai Lab China bridging study. A new entrant marching head-on into 1L naked-mAb-vs-chemo would be a fast-follower into an occupied, de-risked-but-crowded niche.
Later lines are the experimental frontier, and they're thin.
- 3L+: only CARsgen's CT041 CAR‑T — high-potency but autologous (manufacturing, logistics, eligibility constraints), single-arm Phase 2.
- 2L+: only two assets, both Phase 1 and both single-arm — LaNova's ADC (LM‑302) and Innovent's CD3 bispecific (IBI389).
Modality diversification is just beginning. The field spans mAb → ADC → bispecific TCE → CAR‑T, but everything beyond the naked antibody is still Phase 1–2. No ADC or bispecific has reached registrational scale; CAR‑T is autologous only.
1. Combination with the checkpoint backbone in 1L. Every CLDN18.2 trial here is monotherapy-vs-chemo or single-arm. Nivolumab+chemo defines the 1L immuno-chemo standard, yet no CLDN18.2 asset is positioned in combination with a PD-1. A CLDN18.2 + checkpoint (± chemo) 1L regimen — or a bispecific co-engaging CLDN18.2 and an immune axis — is open whitespace.
2. Registrational later-line strategy. 2L/3L+ is served only by early-phase, single-arm, mostly Chinese-developed assets. A globally-run, controlled Phase 3 in 2L+ (where zolbetuximab is absent) is largely uncontested.
3. Next-gen potent modalities done right. The ADC and TCE entries are Phase 1 only — a differentiated CLDN18.2 ADC (better payload/linker, higher therapeutic index) or an off-the-shelf allogeneic / improved-construct cell therapy (vs CARsgen's autologous CT041) could leapfrog.
4. CLDN18.2-low / heterogeneous-expression patients. Zolbetuximab's pivotal trials select high-expressers (~38% of patients). The CLDN18.2-low majority is therapeutically stranded — a setting where potency-driven modalities (ADC bystander effect, TCE, CAR‑T) could expand the addressable population beyond the naked-mAb-eligible segment.
5. Biomarker-stratified / earlier-stage settings. No neoadjuvant/adjuvant or perioperative CLDN18.2 trial appears in this dataset — an entirely open window given activity already shown in advanced disease.
The naked-antibody, high-expresser, 1L-vs-chemo lane is saturated and de-risked by Astellas. The genuine whitespace clusters in: (a) checkpoint-combination 1L regimens, (b) controlled later-line registrational paths, (c) higher-potency/off-the-shelf modalities, and (d) the CLDN18.2-low population and earlier disease stages — none of which are credibly addressed by the current field.
Caveat: this analysis reflects the trials in this database (6 CLDN18.2 + 1 PD‑1 record); a full landscape would also include Phase 1 assets and non-gastric indications not captured here.
| Drug | Sponsor | Modality | Phase | Line | Status | N | Design |
|---|---|---|---|---|---|---|---|
| Zolbetuximab | Astellas (SPOTLIGHT) | Naked mAb | 3 | 1L | Completed | 565 | vs chemo, PFS |
| Zolbetuximab | Astellas (GLOW) | Naked mAb | 3 | 1L | Completed | 507 | vs chemo, OS |
| Zolbetuximab | Zai Lab (China bridge) | Naked mAb | 3 | 1L | Active | 200 | vs chemo, PFS |
| CT041 (satri-cel) | CARsgen | Autologous CAR‑T | 2 | 3L+ | Recruiting | 100 | Single arm, ORR |
| LM‑302 | LaNova | ADC | 1 | 2L+ | Recruiting | 60 | Single arm |
| IBI389 | Innovent | CD3 bispecific (TCE) | 1 | 1 | 2L+ | Recruiting | 80 |
(Context: the only PD‑1 asset in this dataset for the indication is BMS nivolumab+chemo, 1L, the established checkpoint backbone.)
1L is owned by the naked-antibody class. Zolbetuximab is the validated first mover and effectively the standard-setter — two completed Phase 3s (PFS + OS readouts) plus a Zai Lab China bridging study. A new entrant marching head-on into 1L naked-mAb-vs-chemo would be a fast-follower into an occupied, de-risked-but-crowded niche.
Later lines are the experimental frontier, and they're thin.
- 3L+: only CARsgen's CT041 CAR‑T — high-potency but autologous (manufacturing, logistics, eligibility constraints), single-arm Phase 2.
- 2L+: only two assets, both Phase 1 and both single-arm — LaNova's ADC (LM‑302) and Innovent's CD3 bispecific (IBI389).
Modality diversification is just beginning. The field spans mAb → ADC → bispecific TCE → CAR‑T, but everything beyond the naked antibody is still Phase 1–2. No ADC or bispecific has reached registrational scale; CAR‑T is autologous only.
1. Combination with the checkpoint backbone in 1L. Every CLDN18.2 trial here is monotherapy-vs-chemo or single-arm. Nivolumab+chemo defines the 1L immuno-chemo standard, yet no CLDN18.2 asset is positioned in combination with a PD-1. A CLDN18.2 + checkpoint (± chemo) 1L regimen — or a bispecific co-engaging CLDN18.2 and an immune axis — is open whitespace.
2. Registrational later-line strategy. 2L/3L+ is served only by early-phase, single-arm, mostly Chinese-developed assets. A globally-run, controlled Phase 3 in 2L+ (where zolbetuximab is absent) is largely uncontested.
3. Next-gen potent modalities done right. The ADC and TCE entries are Phase 1 only — a differentiated CLDN18.2 ADC (better payload/linker, higher therapeutic index) or an off-the-shelf allogeneic / improved-construct cell therapy (vs CARsgen's autologous CT041) could leapfrog.
4. CLDN18.2-low / heterogeneous-expression patients. Zolbetuximab's pivotal trials select high-expressers (~38% of patients). The CLDN18.2-low majority is therapeutically stranded — a setting where potency-driven modalities (ADC bystander effect, TCE, CAR‑T) could expand the addressable population beyond the naked-mAb-eligible segment.
5. Biomarker-stratified / earlier-stage settings. No neoadjuvant/adjuvant or perioperative CLDN18.2 trial appears in this dataset — an entirely open window given activity already shown in advanced disease.
The naked-antibody, high-expresser, 1L-vs-chemo lane is saturated and de-risked by Astellas. The genuine whitespace clusters in: (a) checkpoint-combination 1L regimens, (b) controlled later-line registrational paths, (c) higher-potency/off-the-shelf modalities, and (d) the CLDN18.2-low population and earlier disease stages — none of which are credibly addressed by the current field.
Caveat: this analysis reflects the trials in this database (6 CLDN18.2 + 1 PD‑1 record); a full landscape would also include Phase 1 assets and non-gastric indications not captured here.
Deterministic summary over the curated trial set for the queried indication. A strong agent should recover the leaders, the phase/modality mix, and credible whitespace.
| Metric | Value | Note |
|---|---|---|
| Trials in scope | 7 | indication = Gastric/GEJ |
| By phase | PHASE1:2, PHASE2:1, PHASE3:4 | |
| By modality | Naked monoclonal antibody:3; CAR-T (autologous):1; Antibody-drug conjugate:1; T-cell engager (bispecific):1; Checkpoint inhibitor (mAb):1 | |
| Top sponsors | Astellas:2; CARsgen:1; LaNova Medicines:1 | |
| Whitespace (modality @ line, no active trial) | Antibody-drug conjugate @ 1L; Antibody-drug conjugate @ 3L+; CAR-T (autologous) @ 1L; CAR-T (autologous) @ 2L+; Checkpoint inhibitor (mAb) @ 1L; Checkpoint inhibitor (mAb) @ 2L+; Checkpoint inhibitor (mAb) @ 3L+; Naked monoclonal antibody @ 2L+ ... |